Cagrilintide

CAS Registry Number: 1415456-99-3

Molecular formula: C₁₇₅H₂₇₅N₅₃O₅₂

Molecular weight: 4051 g/mol

Cagrilintide (Long-Acting Amylin Analogue)  is a novel, long-acting amylin analogue currently under investigation for its potential role in appetite regulation, weight management, and overall metabolic health. As a synthetic analogue of the naturally occurring hormone amylin—co-secreted with insulin—Cagri is designed to amplify amylin’s effects on satiety, food intake, and glucose regulation.

Key Research Highlights:

• Appetite Suppression & Satiety:
  Cagri mimics amylin’s ability to enhance feelings of fullness and reduce hunger. This makes it a promising compound for appetite regulation research, particularly in studies focused on obesity, binge eating, and other disordered eating behaviors.

• Weight Management Potential:
  By slowing gastric emptying and promoting satiety, Cagri helps reduce caloric intake—positioning it as a strong candidate for weight loss and obesity intervention research.

• Combination Therapy Synergy:
  Cagri may work synergistically with other compounds, such as GLP-1 receptor agonists (e.g., semaglutide), to enhance metabolic outcomes. Researchers studying multi-pathway interventions for weight and metabolic regulation may find it especially valuable.

• Glucose Regulation & Metabolic Support:
  As an amylin analogue, Cagri supports glucose homeostasis by slowing nutrient absorption and improving insulin sensitivity—making it relevant for research on type 2 diabetes, insulin resistance, and glycemic control.

• Metabolic Disorder Research:
  Cagri is also being explored in the context of broader metabolic disorders, such as metabolic syndrome and dyslipidemia, due to its dual role in energy intake regulation and glucose metabolism.

• Extended Duration of Action:
  With its long-acting profile, Cagri offers sustained effects on satiety and metabolic control, making it ideal for long-term research studies.